This study is an extension to study MA21573, which is an open label single arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or combination therapy with non-biological disease-modifying antirheumatic drugs, in patients with moderate to severe active rheumatoid arthritis. Patients who complete the 24 week core study, and have at least a moderate response, are eligible to enter this long-term extension study, and will receive tocilizumab 8mg/kg iv every 4 weeks.The anticipated time on study treatment is 1-2 years, and the target sample size is >500 individuals.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT00883753?cond=%22Arthritis%22&lup_s=08/23/2013&lup_d=30
